-+ 0.00%
-+ 0.00%
-+ 0.00%

Elicio Therapeutics reports preclinical AMP-DNA adjuvant study in Science Advances showing durable T-cell responses

PUBT·06/01/2026 12:01:08
Listen to the news
Elicio Therapeutics reports preclinical AMP-DNA adjuvant study in Science Advances showing durable T-cell responses
  • Elicio Therapeutics reported preclinical results in a peer-reviewed Science Advances publication on its AMP-DNA adjuvant platform.
  • Results have already been presented through the journal article, not a future conference or clinical readout.
  • Studies showed stronger, longer-lasting immune responses than benchmark adjuvants, supporting broader use of the AMP platform beyond existing programs.
  • Data in animal models, including non-human primates, suggest potential translational relevance for future oncology or infectious-disease development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010800PRIMZONEFULLFEED9729011) on June 01, 2026, and is solely responsible for the information contained therein.